Table 2.
Predictors of inferior survival* following failure of venetoclax plus hypomethylating agents in 71 patients with acute myeloid leukemia relapsed or refractory to frontline therapy with venetoclax plus hypomethylating agents.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.